Clinical Trials Logo

Renal Insufficiency clinical trials

View clinical trials related to Renal Insufficiency.

Filter by:

NCT ID: NCT01962116 Completed - Clinical trials for Patients With Acute Renal Insufficiency

Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU

VERROU-REA
Start date: June 14, 2013
Phase: Phase 3
Study type: Interventional

After obtaining written informed consent and inclusion, patients will be randomised into 2 groups for the type of dialysis catheter lock: - The first group will have a citrate lock - The second group will have a heparin lock Patients will be stratified according to the centre and type of Renal Replacement Therapy (RRT) continuous or intermittent. The daily surveillance of patients will not be different from the usual surveillance of patients on Renal Replacement Therapy. The hemodialysis catheters used will be specific Renal Replacement Therapy catheters. The decision to withdraw the catheter will be made by the investigator and based on clinical criteria (complications related to the catheter, termination of Renal Replacement Therapy…)

NCT ID: NCT01962025 Completed - Renal Failure Clinical Trials

Buttonhole Versus Step Ladder Cannulation in High Dose Hemodialysis

Start date: October 2013
Phase: N/A
Study type: Interventional

The purpose of the pilot study is to determine: 1) Will patients agree to be randomized to two different methods of putting needles in their arteriovenous fistula and, 2) if we can adequately coordinate all of the sites to get useful multicentre trial data

NCT ID: NCT01958281 Completed - HCV Infection Clinical Trials

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

Start date: October 7, 2013
Phase: Phase 2
Study type: Interventional

The primary objectives of this study are to evaluate the safety and efficacy of sofosbuvir (SOF) plus ribavirin (RBV) for 24 weeks and ledipasvir/sofosbuvir (LDV/SOF) for 12 weeks, and to evaluate the steady state pharmacokinetics (PK) of SOF and its metabolites and LDV in participants with genotype (GT) 1, 3, or 4 hepatitis C virus (HCV) infection who have chronic renal insufficiency (impaired kidney function).

NCT ID: NCT01957657 Completed - Renal Insufficiency Clinical Trials

Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients

Start date: October 2013
Phase: Phase 1
Study type: Interventional

The objective of the trial is to investigate the effect of different degrees of renal impairment on the pharmacokinetics and safety of the combination of BI 207127 and faldaprevir after 3 days of dosing (BI 207127 bid, faldaprevir qd) and a single dose of BI 207127 and faldaprevir on day 4.

NCT ID: NCT01948986 Completed - Clinical trials for Type 2 Diabetes Mellitus

Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)

Start date: October 1, 2013
Phase: Phase 1
Study type: Interventional

This is a study to evaluate the effect of renal impairment on the pharmacokinetics, pharmacodynamics, safety and tolerability of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and in healthy participants with normal renal function.

NCT ID: NCT01948336 Completed - Clinical trials for Hemodynamic Instability

The Effects of Dexmedetomidine on Early Stage Renal Functions in Pediatric Patients

Start date: April 2012
Phase: Phase 4
Study type: Interventional

The aim of this study is to evaluate the effect of dexmedetomidine infusion on early stage renal function.

NCT ID: NCT01946113 Completed - Acute Renal Failure Clinical Trials

Mineral-Homeostasis in Continuous Renal Replacement Therapy

Start date: September 2013
Phase: N/A
Study type: Observational

Acute renal failure is a common complication in intensive care unit patients. In 10% of cases renal replacement therapy becomes necessary. Current devices have increase filter patency and efficacy. However, magnesium, calcium and phosphate are eliminated as well. However, the extend of this elimination hase not been quantified. Thus, we want to 1. record retrospectively how often abnormal values for phosphate, magnesium and calcium occurred during routine renal replacement therapy in 2011 and 2012. 2. prospectively evaluate the same parameters during routine treatment in 2013 and 2014

NCT ID: NCT01945125 Completed - Clinical trials for Other Impaired Renal Function Disorder

Effects of THW and rhTSH in Glomerular Filtration Rate During RIT

Start date: October 2011
Phase: N/A
Study type: Interventional

To observe the influence of thyroid hormone withdrawal and of recombinant human TSH during radioiodine therapy in renal function.

NCT ID: NCT01944852 Completed - Renal Insufficiency Clinical Trials

Efficacy and Safety of a Double Icodextrin Dose in Elderly Incident CAPD Patients on Incremental PD.

DIDo
Start date: March 2013
Phase: Phase 4
Study type: Interventional

The DIDo study is an open-label, randomised, multicentre study with 2 parallel groups in incident CAPD patients aged of 65 at minimum : - One group in which patients will receive 2 bags of icodextrin/day and 1 bag of glucose - One group in which patients will receive 1 bag of icodextrin/day and 2 bags of glucose.

NCT ID: NCT01941823 Completed - Acute Renal Failure Clinical Trials

Carnitine, Aclycarnitine, Myocardial Function, and CRRT

Start date: December 2014
Phase:
Study type: Observational

Carnitine is essential for the transport of fatty acids into the mitochondria and energy production in different muscles, including the myocardium. It is also needed to protect myocyte cell membranes from oxidative damage by removing excess acyl carnitine groups. Patients receiving chronic intermittent hemodialysis (HD) are known to be at increased risk for carnitine deficiency as a result of its removal during the dialysis procedure, lack of endogenous synthesis by the kidney, and inadequate dietary intake. The carnitine status of children undergoing continuous renal replacement therapy (CRRT) has not been studied. Children undergoing CRRT in the intensive care unit (ICU) setting may be at increased risk for carnitine deficiency due to its continuous removal, lack of carnitine production by the kidney, and absence of carnitine intake (as majority of these children can not eat and there is no carnitine added to total parenteral nutrition (TPN). Carnitine deficiency may increase the risk of cardiac dysfunction in critically ill children. This is the first study to examine carnitine status in children undergoing CRRT. Standard echo as well as more sensitive speckle tracking echo will be used to evaluate the effect of carnitine deficiency on myocardial function.